The role of anti-Müllerian hormone in the diagnostics of polycystic ovary syndrome in adolescence (review)
https://doi.org/10.14341/probl201662456-59
Abstract
Polycystic ovary syndrome (PCOS) is the most common cause of hyperandrogenism in women. The criteria for diagnosis in women of reproductive age at present are subject to dispute. At the same time, diagnosis in adolescent girls is associated with even greater challenges, since many of the manifestations of the disease are a manifestation of normal puberty. In the absence of clear criteria for diagnosis in adolescence, more attention is paid to the search for new markers PCOS, one of which may be anti-Müllerian hormone. However, data on its diagnostic value is currently controversial, which calls for more extensive research in order to develop specific criteria for the diagnosis PCOS in teenagers.
About the Authors
Elena L. Soboleva
Federal Almazov North-West Medical Research Centre
Russian Federation
MD, PhD, Professor
Competing Interests:
Russian Federation
MD, PhD, Professor
Competing Interests:
No conflict of interest
Elena S. Vlasova
Federal Almazov North-West Medical Research Centre
Russian Federation
Resident
Competing Interests:
Russian Federation
Resident
Competing Interests:
No conflict of interest
Irina E. Zazerskaya
Federal Almazov North-West Medical Research Centre
Russian Federation
MD, PhD
Competing Interests:
Russian Federation
MD, PhD
Competing Interests:
No conflict of interest
References
1. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012; 97(1):28-38.e2. doi: 10.1016/j.fertnstert.2011.09.024
2. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell. 1992;377-384.
3. The Rotterdam ESHRE/ASRM-Sponsored Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. doi: 10.1016/j.fertnstert.2003.10.004
4. Metcalf MG, Skidmore DS, Lowry GF, Mackenzie JA. Incidence of ovulation in the years after the menarche. J Endocrinol. 1983;97(2):213-219. doi: 10.1677/joe.0.0970213
5. Venturoli S, Porcu E, Fabbri R, et al. Menstrual irregularities in adolescents: hormonal pattern and ovarian morphology. Horm Res. 1986;24(4):269-279. doi: 10.1159/000180567
6. van Hooff MH, Voorhorst FJ, Kaptein MB, et al. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Hum Reprod. 2004;19(2):383-392. doi: 10.1093/humrep/deh079
7. Venturoli S, Porcu E, Fabbri R, et al. Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatr Res. 1995;38(6):974-980. doi: 10.1203/00006450-199512000-00024
8. Довженко Т.В., Ильина Н.А., Гродницкая Е.Э. Проблема психических нарушений при синдроме поликистозных яичников. // Социальная и клиническая психиатрия. — 2015. — Т. 25. — № 2. — С. 94-100. [ Dovzhenko TV, Ilyina NA, Grodnitskaya EE. Mental disorders in persons with polycystic ovary syndrome. Sotsial’naya i klinicheskaya psikhiatriya. 2015;25(2):94-100. (In Russ.)].
9. Cate RL, Mattaliano RJ, Hession C, et al. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell. 1986;45(5):685-698. doi.org/10.1016/0092-8674(86)90783-X
10. Cohen-Haguenauer O, Picard JY, Mattéi MG, et al. Mapping of the gene for anti-Müllerian hormone to the short arm of human chromosome 19. Cytogenet. Cell Genet. 1987;44(1):2-6. doi: 10.1159/000132332
11. Imbeaud S, Faure E, Lamarre I, et al. Insensitivity to anti-Müllerian hormone due to a mutation in the human anti-Müllerian hormone receptor. Nat Genet. 1995;11:382-388. doi: 10.1038/ng1295-382
12. Josso N, Clemente N. Transduction pathway of anti-Müllerian hormone, a sex-specific member of the TGF-β family. Trends Endocrinol Metab. 2003;14(2):91-97. doi: 10.1016/S1043-2760(03)00005-5
13. Weenen C, Laven JS, von Bergh AR, et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10(2):77-83. doi: 10.1093/molehr/gah015
14. Jeppesen JV, Anderson RA, Kelsey TW, et al. Which follicles make the most anti-Müllerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod. 2013;19(8):519-527. doi: 10.1093/molehr/gat024
15. Laven JS, Mulders AG, Visser JA, et al. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004;89(1):318-323. doi.org/10.1210/jc.2003-030932
16. Pellatt L, Hanna L, Brincat M, et al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2007;92(1):240-245. doi: 10.1210/jc.2006-1582
17. Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(3):941-945. doi: 10.1210/jc.2005-2076
18. Dewailly D, Gronier H, Poncelet E, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26(11):3123-3129. doi: 10.1093/humrep/der297
19. Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and metaanalysis of extracted data. J Clin Endocrinol Metabol. 2013;98(8):3332-3340. doi: 10.1210/jc.2013-1393
20. Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Hum Reprod. 2012;27(8):2494-2502. doi: 10.1093/humrep/des213
21. Гродницкая Е.Э., Щербатюк Ю.В., Бендусов И.А., и др. Антимюллеров гормон как маркер синдрома поликистозных яичников.// Проблемы репродукции. — 2013. — №6. — С.27-30. [Grodnitskaia EE, Shcherbatiuk YuV, Bendusov IA, et al. Аnti-müllerian hormone as a diagnostic marker of polycystic ovary syndrome. Modern reproductive technologies. 2013;(6):27-30. (In Russ.)].
22. Li L, Chen X, Mo Y, et al. Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome. Wien Klin Wochenschr. 2010;122(17):519-524. doi: 10.1007/s00508-010-1426-x
23. Hart R, Doherty DA, Norman RJ, et al. Serum anti-mullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril. 2010;94(3):1118-1121. doi: 10.1016/j.fertnstert.2009.11.002
24. Piltonen T, Morin-Papunen L, Koivunen R, et al. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod. 2005;20(7):1820-1826. doi: 10.1093/humrep/deh850
25. Nardo LG, Yates AP, Roberts SA, et al. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod. 2009;24(11):2917-2923. doi: 10.1093/humrep/dep225
26. Carlsen SM, Vanky E, Fleming R. Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum Reprod. 2009;24(7):1732-1738. doi: 10.1093/humrep/dep074
27. Piouka A, Farmakiotis D, Katsikis I, et al. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Phys Endocrinol Metab. 2009;296(2):E238-E243. doi: 10.1152/ajpendo.90684.2008
28. Pinola P, Morin-Papunen LC, Bloigu A, et al. Anti-Müllerian hormone: correlation with testosterone and oligo- or amenorrhoea in female adolescence in a population-based cohort study. Hum Reprod. 2014;29(10):2317-2325. doi: 10.1093/humrep/deu182
29. Cui L, Qin Y, Gao X, et al. Antimullerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause. Fertil Steril. 2016;105(2):481-485e.1. doi: 10.1016/j.fertnstert.2015.10.017
30. Cengiz H, Ekin M, Dagdeviren H, et al. Comparison of serum anti-Müllerian hormone levels in normal weight and overweight-obese adolescent patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2014;180:46-50. doi: 10.1016/j.ejogrb.2014.06.018
31. Pawelczak M, Kenigsberg L, Milla S, et al. Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features. J Pediatr Endocrinol Metab. 2012;25(9-10):983-989. doi: 10.1515/jpem-2012-0013
32. Siow Y, Kives S, Hertweck P, et al. Serum Müllerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Fertil Steril. 2005;84(4):938-944. doi: 10.1016/j.fertnstert.2005.02.052
Supplementary files
Review
For citations:
Soboleva E.L., Vlasova E.S., Zazerskaya I.E. The role of anti-Müllerian hormone in the diagnostics of polycystic ovary syndrome in adolescence (review). Problems of Endocrinology. 2016;62(4):56-59. (In Russ.) https://doi.org/10.14341/probl201662456-59
Views:
3920
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
